Urigen Pharmaceuticals, Inc.
Urigen Pharmaceuticals Announces a Partial Debt Restructuring
Published in Pharma Investments, Ventures and Law Weekly, November 15th, 2009
"As we continue to pursue strategic alternatives, we are pleased that the majority of our unsecured note holders have converted $537,000 of their notes and $109,587 of accrued interest into common stock of the Company," said Urigen's CFO Martin E. Shmagin. "We are also pleased that our lead institutional investor, Platinum-Montaur Life Sciences LLC, has agreed to a six month extension on the maturity of our secured debt." About Urigen...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Investments, Ventures and Law Weekly
More Articles from Pharma Investments, Ventures and Law Weekly
- AARP Idaho
AARP Says Idaho on Crash Course With Health Care Disaster - Addus HomeCare
Addus HomeCare Corporation Prices Initial Public Offering - Allergan, Inc.
Allergan Announces Victory in Brimonidine Patent Infringement Case - Amazon Defense Coalition
Amazon Defense Coalition: Chevron Admits Its Lawyers Present at Key Meeting with Ecuador Man Who Taped Video Scandal - American CareSource Holdings, Inc.
American CareSource To Present at Oppenheimer Healthcare Conference - Americans for Tax Reform
Taxpayer Group Launches Petition to Ask Sen. Ben Nelson to Keep His Pledge - More from this issue of Pharma Investments, Ventures and Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
